China-based HiRO acquires CRO DeltaMed Solutions to expand cross-border operations in US

China-based Harvest Integrated Research Organization (HiRO), a full-service, boutique global contract research organisation (CRO), has announced its latest strategic move with the successful acquisition of DeltaMed Solutions, an emerging CRO with a robust foothold in the US. The acquisition, advised by Evercore as financial advisor, marks HiRO's third CRO acquisition since its establishment in 2020.

Following the acquisitions of ANZ-based PharmaSols in 2021 and US-based Courante Oncology last year, HiRO's global expansion continues with the integration of DeltaMed Solutions.

With its established footprint in the US, Ireland, Mainland China, Taiwan, Australia, New Zealand, Japan, South Korea, Malaysia, and the Philippines, HiRO solidifies its position as a comprehensive provider of end-to-end clinical research solutions on a global scale.

The full integration of DeltaMed Solutions into HiRO's operations will foster a powerful alliance, leveraging the expertise of both companies in key therapeutic areas and service offerings. This broadens HiRO's network of clients and partners, and enhances its ability to deliver capital-efficient, expedited, and customized clinical trial solutions, addressing the unmet R&D needs of pharmaceutical and biotech companies worldwide.

With this strategic acquisition, HiRO and DeltaMed Solutions join forces to provide an unparalleled range of services, delivering bespoke and efficient clinical trial solutions that effectively navigate market-specific complexities globally.